Conditions: Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory Non-Hodgkin Lymphoma; Pancreatic Adenocarcinoma; Resistant Cancer; Neoplasm Metastasis; Neoplasm of Bone; Neoplasm, Breast; Neoplasm of Lung; Neoplasms,Colorectal; Neoplasms Pancreatic; Malignant Glioma; Malignancies; Malignancies Multiple; Bone Metastases; Bone Neoplasm; Bone Cancer; Pancreas Cancer; Pancreatic Neoplasms; Breast Neoplasms; Acute T Cell Leukemia Lymphoma
Interventions: Drug: 9-ING-41; Drug: Gemcitabine – 21 day cycle; Drug: Doxorubicin.; Drug: Lomustine; Drug: Carboplatin.; Drug: Nab paclitaxel.; Drug: Paclitaxel.; Drug: Gemcitabine – 28 day cycle; Drug: Irinotecan
Sponsors: Actuate Therapeutics Inc.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.